| Vol. 11.49 – 15 December, 2020 |
| |
|
|
| The authors showed that ATP levels were markedly increased in the bone marrow niches of mice with acute myeloid leukemia, and leukemia-initiating cells preferred to localize to the endosteal niche with relatively high ATP levels, as indicated by a sensitive ATP indicator. [Journal of Clinical Investigation] |
|
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Scientists demonstrated that the inv(16)/KITD816Y AML mouse model exhibited constitutive activation of PI3K/AKT signaling, which was enhanced by chemotherapy-induced DNA damage through DNA-PK-dependent AKT phosphorylation. [Leukemia] |
|
|
|
| Investigators unveiled that deletion of Nupr1, a gene preferentially expressed in hematopoietic stem cells (HSCs), activated the quiescence HSCs under homeostatic status, which conferred engraftment competitive advantage on HSCs without compromising their stemness and multi-lineage differentiation abilities in serial transplantation settings. [Haematologica] |
|
|
|
| The authors combined single-cell profiling with machine learning and in vivo functional studies to explore how hematopoietic stem cell divisions patterns evolve with age. [Cell Systems] |
|
|
|
| Researchers showed that pervasive and dynamic alternative splicing takes place during hematopoietic development of human pluripotent stem cells. They identified a splicing factor switch that occurs during the differentiation of mesodermal cells to endothelial progenitor cells. [EMBO Reports] |
|
|
|
| The authors developed a scalable suspension agitation culture platform for differentiating human induced pluripotent stem cell-microcarrier aggregates into functional red blood cells and have demonstrated scalability of the process starting with six well plates and finally demonstrating in 500 mL spinner flasks. [Stem Cell Reports] |
| |
|
|
| The Phase II HORIZON trial evaluated the efficacy of melflufen plus dexamethasone in relapsed and refractory multiple myeloma, a population with an important unmet medical need. [Journal of Clinical Oncology] |
|
|
|
| Scientists retrospectively compared outcomes of a large series of adult patients with APL in CR2 receiving alloHSCT or autoHSCT reported to the European Society for Blood and Marrow Transplantation from January 2004 to December 2018. [Bone Marrow Transplantation] |
|
|
|
| Researchers report the outcome of 34 patients with Fanconi anemia inside a collaborative multicenter national study based on recommendations of Spanish Working Group for Bone Marrow Transplantation in Children between 2009 and 2016. [Bone Marrow Transplantation] |
|
|
|
|
| The authors review the most recent advances in hematopoietic stem and progenitor cell (HSPC) gene therapy and discuss emerging strategies for using HSPC gene therapy for a range of diseases. [Nature Reviews Genetics] |
|
|
|
|
| Graphite Bio announced that the FDA has cleared its investigational new drug application (IND) for the experimental gene editing therapy GPH101 to initiate a Phase I/II clinical trial in patients with severe sickle cell disease. [Graphite Bio] |
|
|
|
|
| January 25 – 28, 2021 Virtual |
|
|
|
|
|
| NIH National Cancer Institute – Bethesda, Maryland, United States |
|
|
|
| Rubius Therapeutics – Cambridge, Massachusetts, United States |
|
|
|
| St. Jude Children’s Research Hospital – Memphis, Tennessee, United States |
|
|
|
| Stanford University – Stanford, California, United States |
|
|
|
| New York Blood Center – New York, New York, United States |
|
|
|
|